Algorae Signs Three-Year NSW Health Supply Arrangement

Strategic Supply Appointment to NSW Health

Algorae Pharmaceuticals Ltd (ASX:1AI) has secured a foothold in one of Australia's largest healthcare procurement networks by becoming an approved supplier under a NSW Health standing offer arrangement. The contract, awarded to Algorae's commercial division AlgoraeRx following a competitive tender, enables supply of a pharmaceutical product to public hospitals and other eligible customers across New South Wales.

While the specific product and pricing remain commercial-in-confidence, the arrangement's strategic significance lies in opening access to a vast public hospital market. The contract spans an initial three-year term with options to extend for two additional one-year periods, positioning Algorae to build its commercial presence in the Australian healthcare sector.

Non-Exclusive Contract with Flexible Volumes

The arrangement is non-exclusive and does not bind NSW Health's Eligible Customers to minimum purchase volumes or spend. This means local health districts and public hospitals can place orders at agreed prices but are under no obligation to do so. Algorae acknowledges this uncertainty, noting that while the contract is a material step for its revenue pathway, it does not currently allow quantification of financial impact.

First supply under purchase orders is expected in the fourth quarter of 2026, with onboarding and rollout already underway. There are no conditions precedent to commencing supply, suggesting a smooth transition from contract award to market delivery.

Balancing Confidentiality and Disclosure Obligations

Algorae is bound to maintain confidentiality over pricing and volume details, consistent with ASX guidance and commercial sensitivities. However, the company remains committed to its continuous disclosure obligations and will update the market if it receives purchase orders that are material individually or in aggregate.

This approach reflects a common tension for pharmaceutical suppliers operating within public health frameworks: balancing transparency with competitive confidentiality. Investors will need to monitor future disclosures to assess the contract's revenue contribution as orders materialise.

Algorae’s Dual-Track Strategy in Play

This supply contract complements Algorae's broader dual-track strategy that combines AI-driven drug discovery with pharmaceutical commercialisation. While the AI platform AlgoraeOS continues to generate promising drug combination candidates, the AlgoraeRx division is building a revenue base through specialty and generic medicine supply in Australia and New Zealand.

Securing a NSW Health supply role aligns with recent moves to expand commercial partnerships and regulatory progress, underpinning the company's ambition to translate AI innovations into tangible market presence and income streams.